 AI Writes Code, Cars Drive Themselves, Pharma Pays Billions: Three News Stories from One Week May 2026 turned out to be eventful for those following automation and artificial intelligence. In one week, three events occurred that show: AI has ceased to be an experiment and has become a working tool in heavy industry. **GM: 90% of Autopilot Code Written by Neural Network** Mary Barra stated during the Q1 2026 earnings call that nearly 90% of the code for Super Cruise (GM's autonomous driving system) is generated by artificial intelligence. This is not hype—it's the new reality of R&D. GM engineers now primarily review and refine AI-generated code rather than writing it from scratch. The question is not whether AI will replace programmers, but how quickly companies without AI code generation will fall out of the race. **Nissan: AI Autopilot in 90% of Models** Nissan announced that the next generation of ProPILOT with end-to-end autonomy will be available in 90% of its model lineup. Tests in Tokyo showed that the system drives at the level of an experienced driver, and in some places, even better. This means that mass-market consumers are getting technologies that were once the prerogative of Waymo and Tesla. **Eli Lilly Pays $2.75 Billion for AI Drug Development** The pharmaceutical giant signed a deal with Insilico Medicine worth up to $2.75 billion. Insilico uses an AI platform to search for and design new molecules—a process that used to take years now fits into months. This is the largest confirmation that biotech and AI have finally merged into one market. **What Does This Mean?** All three news stories are about the same thing: automation is no longer the domain of startups. GM, Nissan, Eli Lilly—major players embedding AI into the core of their business. For us, this is a signal: the market is ripe for products that help businesses analyze data and automate routine tasks. Those who don't start now will be catching up with a two-fold lag in a year.